Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
Chen Chen, Bin Wu, Chenyu Zhang, Ting Xu
Topics & Concepts
DurvalumabIpilimumabMedicineAdverse effectNivolumabPembrolizumabInternal medicinePneumonitisAdverse Event Reporting SystemFingolimodOncologyImmunologyCancerImmunotherapyLungMultiple sclerosisCancer Immunotherapy and BiomarkersCAR-T cell therapy researchColorectal Cancer Treatments and Studies